The Therapeutic Goods Administration has advised of the addition of Orfadin (nitisinone) to the list of designated orphan drugs.
Orfadin is sponsored by Orphan Australia Pty Ltd and is indicated for the treatment of hereditary tyrosinaemia type 1.
For further info see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Sep 16